332 related articles for article (PubMed ID: 2150552)
21. Oral ondansetron (GR 38032F) for the control of CMF-induced emesis in the outpatient.
Campora E; Oliva C; Mammoliti S; Cetto GL; Fosser V; Marangolo M; Rosso R
Breast Cancer Res Treat; 1991 Oct; 19(2):129-32. PubMed ID: 1836746
[TBL] [Abstract][Full Text] [Related]
22. Ondansetron, an antagonist of 5-HT3 receptors, in the treatment of antineoplastic drug-induced nausea and vomiting in children.
Matera MG; Di Tullio M; Lucarelli C; Casale F; Calabria C; Lampa E; Indolfi P; Rossi F
J Med; 1993; 24(2-3):161-70. PubMed ID: 7691978
[TBL] [Abstract][Full Text] [Related]
23. Parenteral ondansetron for the treatment of chemotherapy- and radiation-induced nausea and vomiting.
Burnette PK; Perkins J
Pharmacotherapy; 1992; 12(2):120-31. PubMed ID: 1533280
[TBL] [Abstract][Full Text] [Related]
24. Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis.
Kris MG; Tyson LB; Clark RA; Gralla RJ
Cancer; 1992 Aug; 70(4 Suppl):1012-6. PubMed ID: 1386282
[TBL] [Abstract][Full Text] [Related]
25. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
26. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
Bonneterre J; Chevallier B; Metz R; Fargeot P; Pujade-Lauraine E; Spielmann M; Tubiana-Hulin M; Paes D; Bons J
J Clin Oncol; 1990 Jun; 8(6):1063-9. PubMed ID: 2140854
[TBL] [Abstract][Full Text] [Related]
27. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
Slabý J; Trnený M; Procházka B; Klener P
Neoplasma; 2000; 47(5):319-22. PubMed ID: 11130251
[TBL] [Abstract][Full Text] [Related]
28. Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron.
du Bois A; Meerpohl HG; Vach W; Kommoss FG; Fenzl E; Pfleiderer A
Eur J Cancer; 1992; 28(2-3):450-7. PubMed ID: 1534250
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis.
Marty M; Pouillart P; Scholl S; Droz JP; Azab M; Brion N; Pujade-Lauraine E; Paule B; Paes D; Bons J
N Engl J Med; 1990 Mar; 322(12):816-21. PubMed ID: 2137902
[TBL] [Abstract][Full Text] [Related]
30. [Treatment of postoperative nausea and vomiting with ondansetron in patients administered anti-neoplastic agents].
Morimoto Y; Nakamura M; Tamura T; Kunii T; Shimizu K; Miyauchi Y
Masui; 1996 Sep; 45(9):1096-9. PubMed ID: 8905945
[TBL] [Abstract][Full Text] [Related]
31. Antiemetic control: 5-HT3 antagonists: review of clinical results, with particular emphasis on ondansetron.
Kidgell AE; Butcher ME; Brown GW
Cancer Treat Rev; 1990 Sep; 17(2-3):311-7. PubMed ID: 2176933
[No Abstract] [Full Text] [Related]
32. Ondansetron: a new antiemetic for patients receiving cisplatin chemotherapy.
Einhorn LH; Nagy C; Werner K; Finn AL
J Clin Oncol; 1990 Apr; 8(4):731-5. PubMed ID: 2138214
[TBL] [Abstract][Full Text] [Related]
33. Ondansetron (GR 38032F): a novel antiemetic effective in patients receiving a multiple-day regimen of cisplatin chemotherapy.
Hainsworth JD; Omura GA; Khojasteh A; Bryson JC; Finn AL
Am J Clin Oncol; 1991 Aug; 14(4):336-40. PubMed ID: 1830716
[TBL] [Abstract][Full Text] [Related]
34. Use of dexamethasone with 5-HT3-receptor antagonists for chemotherapy-induced nausea and vomiting.
Perez EA
Cancer J Sci Am; 1998; 4(2):72-7. PubMed ID: 9532406
[TBL] [Abstract][Full Text] [Related]
35. Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting.
Markham A; Sorkin EM
Drugs; 1993 Jun; 45(6):931-952. PubMed ID: 7691500
[TBL] [Abstract][Full Text] [Related]
36. Palonosetron is nonsuperior to ondansetron in acute phase but provides superior antiemetic control in delayed phase for pediatric patients administered highly emetogenic chemotherapy.
Tan J; Wang S; Liang X; Li CC; Zhang J; Zhao Z; Kong XR; Deng X; Peng L; Yang C
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28941006
[TBL] [Abstract][Full Text] [Related]
37. Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy.
Perwitasari DA; Wessels JA; van der Straaten RJ; Baak-Pablo RF; Mustofa M; Hakimi M; Nortier JW; Gelderblom H; Guchelaar HJ
Jpn J Clin Oncol; 2011 Oct; 41(10):1168-76. PubMed ID: 21840870
[TBL] [Abstract][Full Text] [Related]
38. Oral ondansetron (GR38032F) for the control of acute and delayed cyclophosphamide-induced emesis.
Rosso R; Campora E; Cetto G; Fosser V; Marangolo M; Oliva C
Anticancer Res; 1991; 11(2):937-9. PubMed ID: 1829602
[TBL] [Abstract][Full Text] [Related]
39. A phase II study of ondansetron as antiemetic prophylaxis in patients receiving high-dose polychemotherapy and stem cell transplantation.
Barbounis V; Koumakis G; Vassilomanolakis M; Hatzichristou H; Tsousis S; Efremidis AP
Support Care Cancer; 1995 Sep; 3(5):301-6. PubMed ID: 8520876
[TBL] [Abstract][Full Text] [Related]
40. Antiemetic activity of ondansetron in cancer patients receiving non-cisplatin chemotherapy.
Fraschini G
Semin Oncol; 1992 Aug; 19(4 Suppl 10):41-7. PubMed ID: 1387249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]